Pfizer Inc. (PFE)

43.68
0.42 0.97
NYSE : Health Technology
Prev Close 43.26
Open 43.37
Day Low/High 43.35 / 43.62
52 Wk Low/High 33.20 / 43.68
Volume 3.43M
Avg Volume 19.11M
Exchange NYSE
Shares Outstanding 5.86B
Market Cap 255.06B
EPS 3.60
P/E Ratio 11.63
Div & Yield 1.36 (3.12%)

Latest News

New Sub-group Analyses From The Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented At 2018 HFSA Annual Scientific Meeting

New Sub-group Analyses From The Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented At 2018 HFSA Annual Scientific Meeting

Pfizer Inc. (NYSE:PFE) announced today that additional sensitivity and post-hoc analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) study provide further detail on the effect of tafamidis across wild-type, hereditary, and...

Pfizer Presents Positive Phase 2 Data In Alopecia Areata During Late-Breaker Session At The 27th European Academy Of Dermatology And Venereology (EADV) Congress

Pfizer Presents Positive Phase 2 Data In Alopecia Areata During Late-Breaker Session At The 27th European Academy Of Dermatology And Venereology (EADV) Congress

Pfizer Inc. (NYSE:PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia...

Pfizer Becomes #19 Most Shorted Dow Stock, Replacing Cisco Systems

Pfizer Becomes #19 Most Shorted Dow Stock, Replacing Cisco Systems

The most recent short interest data has been released for the 08/28/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, at the Morgan Stanley 16 th Annual Global Healthcare Conference on...

Pfizer Receives Breakthrough Therapy Designation From FDA For PF-06651600, An Oral JAK3 Inhibitor, For The Treatment Of Patients With Alopecia Areata

Pfizer Receives Breakthrough Therapy Designation From FDA For PF-06651600, An Oral JAK3 Inhibitor, For The Treatment Of Patients With Alopecia Areata

Pfizer Inc. (NYSE:PFE) today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.

3 Biotech Stocks Ready to Burn Up

3 Biotech Stocks Ready to Burn Up

Biotechs are known for wild tears. Investors, you'll want to consider these drug makers.

Pfizer Prices $5,000,000,000 Debt Offering

Pfizer Prices $5,000,000,000 Debt Offering

Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of six tranches of notes: $300,000,000 aggregate principal amount of floating rate notes due 2023 $1,000,000,000 aggregate principal amount of 3.

Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies For The Treatment Of Duchenne Muscular Dystrophy

Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies For The Treatment Of Duchenne Muscular Dystrophy

Pfizer Inc. (NYSE: PFE) announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label...

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets were higher Tuesday after starting Tuesday's session off in the green.

New Records as Dow and Other Indexes Post Gains on Tentative Mexico Trade Deal

New Records as Dow and Other Indexes Post Gains on Tentative Mexico Trade Deal

The S&P 500 and Nasdaq set record highs as stocks rose Monday after the U.S. and Mexico reached a tentative trade agreement.

Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented As Late-Breaking Data At The ESC Congress 2018

Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented As Late-Breaking Data At The ESC Congress 2018

Pfizer Inc. (NYSE:PFE) announced today the primary results from the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, which showed tafamidis significantly reduced the hierarchical combination of both all-cause mortality and frequency of...

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 8/24/18)

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 8/24/18)

Jim Cramer explains the art and science of technical analysis. Plus, he has next week's game plan.

Don't Forget the Consumer: Cramer's 'Mad Money' Recap (Wednesday 8/22/18)

Don't Forget the Consumer: Cramer's 'Mad Money' Recap (Wednesday 8/22/18)

Jim Cramer says we have a $19 trillion economy, and two-thirds of it is based on consumer spending -- not manufacturing, or sales, or industry.

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.

Pfizer And Astellas Amend Clinical Research Protocols For Two Phase 3 Trials Of Enzalutamide In Patients With Hormone-Sensitive Prostate Cancer

Pfizer And Astellas Amend Clinical Research Protocols For Two Phase 3 Trials Of Enzalutamide In Patients With Hormone-Sensitive Prostate Cancer

Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials

Exact Sciences And Pfizer Enter Into U.S. Promotion Agreement For Cologuard®

Exact Sciences And Pfizer Enter Into U.S. Promotion Agreement For Cologuard®

Collaboration is expected to drive Cologuard adoption through expanded sales and marketing efforts

Pfizer Reached Our Price Target, So We Could Pause Here Before Heading Higher

Pfizer Reached Our Price Target, So We Could Pause Here Before Heading Higher

Traders should raise sell stops to just above $40 from below $35.50

Jim Cramer: This Is a Rotation, Not a Recession

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.

Why Pay a Premium for Estee Lauder?

Why Pay a Premium for Estee Lauder?

EL's stock is up despite a guidance cut.

Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018

Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Monday, August 27, 2018 at 9:00 a.

Investors May Have Omarosa to Thank for Pretty Good Week

Investors May Have Omarosa to Thank for Pretty Good Week

Thanks, Omarosa. And you too, Bob Mueller, for distracting the president this week from trade wars and tariff skirmishes and allowing investors to make some money.

Walmart Fuels Monster Move: Cramer's 'Mad Money' Recap (Thursday 8/16/18)

Walmart Fuels Monster Move: Cramer's 'Mad Money' Recap (Thursday 8/16/18)

Walmart -- with great growth -- sparks optimism, but Jim Cramer says it's not the only stock to fuel the day's rally.

Walmart's Assault on Amazon Looks as if It's Starting to Pay Off in a Big Way

Walmart's Assault on Amazon Looks as if It's Starting to Pay Off in a Big Way

Retail earnings are in full swing with results from Walmart and J.C. Penney. All eyes still on the cannabis space. Big day for tool king Stanley Black & Decker.

Buy Stocks That Are Down, Not Up, Here

Buy Stocks That Are Down, Not Up, Here

Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Time to brace for a summer pullback?

3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick

3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick

The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.

TheStreet Quant Rating: A+ (Buy)